The HIV vaccine saga

  title={The HIV vaccine saga},
  author={Kendall A. Smith},
  journal={Medical Immunology},
  pages={1 - 1}
The development of a vaccine that can prevent infection by the Human immunodeficiency virus or prevent the Acquired Immunodeficiency Syndrome has remained elusive despite 20 years of scientific effort. This "Commentary" analyzes the reasons that the development of a vaccine has been so difficult, and proposes a plan to work towards an immunological approach to investigate the best vaccine candidates in the first world in individuals who are already infected, before taking the most promising… Expand
The prospective preventative HIV vaccine based on modified poliovirus.
It is hypothesize that HIV vaccine based on poliovirus is potential to develop the promising one, because it can elicit the broad immune response including the main mucosal, humoral and cellular reaction. Expand
25 – HIV and Acquired Immunodeficiency Syndrome
HIV is a cytopathic RNA retrovirus causing acquired immunodeficiency syndrome (AIDS) in human hosts and the host factors that influence the course of HIV infection include host resistance to HIV infection and clinical course variability. Expand
Immunotherapy with Canarypox Vaccine and Interleukin-2 for HIV-1 Infection: Termination of a Randomized Trial
Neither ALVAC (vCP1452) nor low-dose daily IL-2 nor their combination prevented the relapse of viremia upon discontinuation of antiviral therapy. Expand
The continuing HIV vaccine saga: naked emperors alongside fairy godmothers
The latest developments in the HIV vaccine field were aired at a Keystone Symposium recently, and some of the developments that appeared particularly promising, as well as those that do not. Expand
Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine.
The utility of bioinformatics tools to select and construct novel "immunogenic consensus sequence" T cell epitopes for a globally relevant vaccine against HIV is confirmed. Expand
Model-Based Anti-HIV Therapy
Modern combination drug therapy has substantially improved the clinical management of HIV-1 infection. Still, the emergence of drug-resistant variants eventually leads to therapy failure in mostExpand
Oncolytic Viruses in the Treatment of Cancer: A Review of Current Strategies
Systemic administrations of oncolytic viruses will successfully extend novel treatment against a range of tumors, and combination therapy has shown some encouraging antitumor responses by eliciting strong immunity against established cancer. Expand
Frontiers in Immunology – Grand Challenges
It is now evident that antigen recognition results in the activation of exquisite negative feedback loops in addition to the generation of marvelously effective immune responses, and whether a detectable systemic immune response occurs or not is decided by the summation of these positive and negative molecular pathways. Expand
Kinetic and Crystallographic Studies of Drug-Resistant Mutants of HIV-1 Protease: Insights into the Drug Resistance Mechanisms
HIV-1 protease (PR) inhibitors (PIs) are important anti-HIV drugs for the treatment of AIDS and have shown great success in reducing mortality and prolonging the life of HIV-infected individuals.Expand
Genotypic analysis of HIV-1 coreceptor usage
Anti-HIV drugs target essential viral proteins in the replication cycle of HIV, to date mostly the viral reverse transcriptase and protease, but the search for new targets is still necessary. Expand


Optimal clinical trial designs for immune-based therapies in persistent viral infections
This commentary explores the rationale of using "Diagnostic Treatment Interruptions" of antiviral therapies to determine efficacies of immune-based therapies. Expand
AIDS: Re-emergence of HIV after stopping therapy
It is shown that this dormant reservoir of HIV rapidly re-emerges within weeks of discontinuing HAART in two patients, and that this re-emergence is associated with the appearance of HIV in the plasma (viraemia) of these patients. Expand
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
The replication-defective adenovirus is a promising vaccine vector for development of an HIV-1 vaccine and elicited by a replication-incompetent Ad5 vector, used either alone or as a booster inoculation after priming with a DNA vector. Expand
To cure chronic HIV infection, a new therapeutic strategy is needed.
  • K. Smith
  • Medicine
  • Current opinion in immunology
  • 2001
This review is focused on the rationale and methods to design clinical trials directed towards achieving a cure of HIV infection, and it is clear that the previous dogma that HIV-specific immune reactivity is absent in individuals who are chronically infected is incorrect. Expand
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
The protective efficacy of vaccine-elicited immune responses against a pathogenic SHIV-89.6P challenge in rhesus monkeys is reported, with no evidence of clinical disease or mortality after challenge. Expand
Viral dynamics in human immunodeficiency virus type 1 infection
Almost complete replacement of wild-type virus in plasma by drug-resistant variants occurs after fourteen days, indicating that HIV-1 viraemia is sustained primarily by a dynamic process involving continuous rounds of de novo virus infection and replication and rapid cell turnover. Expand
AIDS vaccine models: Challenging challenge viruses
Preclinical challenge studies of AIDS vaccines in non-human primates have an important role in the AIDS vaccine development effort. However, to be most useful, challenge models need to be improved toExpand
Control of Viremia and Prevention of Simian-Human Immunodeficiency Virus-Induced Disease in Rhesus Macaques Immunized with Recombinant Vaccinia Viruses plus Inactivated Simian Immunodeficiency Virus and Human Immunodeficiency Virus Type 1 Particles
The results indicate that despite the protection from SHIV-induced disease, the vaccinated animals still harbored replication-competent and pathogenic virus. Expand
Reduction of Simian-Human Immunodeficiency Virus 89.6P Viremia in Rhesus Monkeys by Recombinant Modified Vaccinia Virus Ankara Vaccination
It is demonstrated that immune responses elicited by live recombinant vectors, although unable to provide sterilizing immunity, can control viremia and prevent disease progression following a highly pathogenic AIDS virus challenge. Expand
Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes.
A transgenic mouse model of HBV replication is used to demonstrate that adoptively transferred virus-specific CTLs can abolish HBV gene expression and replication in the liver without killing the hepatocytes. Expand